Objective: To explore the expression of protein associated with phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway in the pathological tissues of patients with cervical cancer

and to analyze the relationship between its expression level and clinical pathological parameters and prognosis of patients. Methods: The biopsy and surgical cervical cancer specimens of 61 patients with cervical cancer who were treated in The First People's Hospital of Zunyi from January 2016 to January 2018 were collected. The expression of PI3K

p-Akt

and p-mTOR was detected by immunohistochemistry. The relationship between the expressions of PI3K

Akt

mTOR and clinicopathological characteristics of patients with cervical cancer was analyzed by multivariate logistic regression model

and the relationship between the expressions of PI3K

Akt

mTOR and prognosis of patients with cervical cancer was analyzed by Kaplan-Meier survival curve. Results: The positive rates of PI3K

p-Akt and p-mTOR in cervical cancer tissues were higher than those in para-cancerous tissues (χ2=64.050

P=0.000; χ2=58.607

P=0.000; χ2=56.637

P=0.000). The expressions of mTOR in cervical cancer patients aged≥45 years were higher than those in patients aged<45 years (χ2=4.163

P=0.041). The expressions of PI3K

Akt

and mTOR in cervical cancer patients with clinical stagesⅢandⅣwere higher than those in patients with clinical stagesⅠandⅡ (χ2=5.610

P=0.018; χ2=5.450

P=0.020; χ2=8.606

P=0.003). The expressions of PI3K

Akt

and mTOR in cervical cancer patients with low-degree of differentiation were higher than those in patients with medium and high-degree of differentiation (χ2=7.062

P=0.029; χ2=10.526

P=0.005; χ2=7.714

P=0.021). The expressions of PI3K

Akt and mTOR in cervical cancer patients with lymph node metastasis were higher than those in patients without lymph node metastasis (χ2=5.643

P=0.018; χ2=6.336

P=0.012; χ2=5.030

P=0.025). There was no statistical difference in the expression levels of PI3K

Akt

and mTOR in cervical cancer patients with different body mass index

menstrual status

tumor diameter

and histological classification (P>0.05). Multivariate logistic analysis showed that the clinical stage

degree of differentiation

and lymph node metastasis of patients with cervical cancer were all independent factors influencing the expression of PI3K

Akt

and mTOR (P<0.05). The median survival time of PI3K

p-Akt

and p-mTOR positive patients were all lower than that of negative patients (P<0.05). Conclusion: There are high expressions of PI3K

Akt

and mTOR in patients with cervical cancer. Clinical stage

degree of differentiation

and lymph node metastasis are all independent factors influencing the expression of PI3K

Akt

mTOR

and the prognosis of patients with high expression is poor.